COMPANY

Mycovia Pharmaceuticals

HQ: Durham, NC source · mycovia.com ↗ · Southeast

Keywords: women's health Recurrent Vulvovaginal Candidiasis Oteseconazole (VT-1161)

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Mar 13, 2019 Trial start Phase 3: Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections source ↗
Aug 23, 2018 Trial start Phase 3: A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) source ↗
Aug 16, 2018 Trial start Phase 3: A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT03561701	A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	Phase 3	Completed	Aug 23, 2018	Oct 13, 2020 (actual)
NCT03562156	A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)	Phase 3	Completed	Aug 16, 2018	Oct 19, 2020 (actual)
NCT03840616	Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections	Phase 3	Completed	Mar 13, 2019	Dec 2, 2020 (actual)

Annual award amounts. Total $985K.

Jun 3, 2016 NIH award 5R33AI101497-05 FY2016: $95,000 awarded for that fiscal year; activity R33 (OTHER_NIH); PI GARVEY, EDWARD P; recipient as written: MYCOVIA PHARMACEUTICALS, INC., DURHAM, NC. Optimized CYP51 Inhibitors for t source ↗
May 6, 2015 NIH award 5R33AI101497-04 FY2015: $373,000 awarded for that fiscal year; activity R33 (OTHER_NIH); PI GARVEY, EDWARD P; recipient as written: MYCOVIA PHARMACEUTICALS, INC., DURHAM, NC. Optimized CYP51 Inhibitors for source ↗
Jun 19, 2014 NIH award 4R33AI101497-03 FY2014: $242,000 awarded for that fiscal year; activity R33 (OTHER_NIH); PI GARVEY, EDWARD P; recipient as written: MYCOVIA PHARMACEUTICALS, INC., DURHAM, NC. Optimized CYP51 Inhibitors for source ↗
May 10, 2013 NIH award 5R21AI101497-02 FY2013: $145,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI GARVEY, EDWARD P; recipient as written: MYCOVIA PHARMACEUTICALS, INC., DURHAM, NC. Optimized CYP51 Inhibitors for source ↗
Jun 10, 2012 NIH award 1R21AI101497-01 FY2012: $130,000 awarded for that fiscal year; activity R21 (OTHER_NIH); PI GARVEY, EDWARD P; recipient as written: MYCOVIA PHARMACEUTICALS, INC., DURHAM, NC. Optimized CYP51 Inhibitors for source ↗